AIMD vs. LIXT, IBIO, PCSA, KA, HILS, XBIO, TFFP, ENVB, SHPH, and PULM
Should you be buying Ainos stock or one of its competitors? The main competitors of Ainos include Lixte Biotechnology (LIXT), iBio (IBIO), Processa Pharmaceuticals (PCSA), Kineta (KA), Hillstream BioPharma (HILS), Xenetic Biosciences (XBIO), TFF Pharmaceuticals (TFFP), Enveric Biosciences (ENVB), Shuttle Pharmaceuticals (SHPH), and Pulmatrix (PULM). These companies are all part of the "pharmaceutical preparations" industry.
Ainos (NASDAQ:AIMD) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, earnings, profitability, institutional ownership, media sentiment, valuation and risk.
Ainos has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500.
In the previous week, Ainos and Ainos both had 1 articles in the media. Ainos' average media sentiment score of 0.38 beat Lixte Biotechnology's score of 0.00 indicating that Ainos is being referred to more favorably in the media.
Ainos and Lixte Biotechnology both received 0 outperform votes by MarketBeat users.
Lixte Biotechnology has lower revenue, but higher earnings than Ainos. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.
Lixte Biotechnology has a net margin of 0.00% compared to Ainos' net margin of -11,205.49%. Ainos' return on equity of -47.96% beat Lixte Biotechnology's return on equity.
5.1% of Lixte Biotechnology shares are held by institutional investors. 4.6% of Ainos shares are held by company insiders. Comparatively, 15.5% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Ainos beats Lixte Biotechnology on 7 of the 11 factors compared between the two stocks.
Get Ainos News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AIMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
